The KDM5D Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional disruption of the KDM5D gene in the near-haploid human HAP1 cell line. This pooled knockout model is generated through CRISPR/Cas9-mediated gene disruption within the coding region of KDM5D, resulting in a heterogeneous population of cells carrying loss-of-function mutations. The polyclonal format maintains genetic diversity and is well-suited for pooled screening and bulk functional assays, offering a cost-effective alternative to single-cell-derived clonal lines while enabling robust assessment of KDM5D-dependent phenotypes. Researchers benefit from a stable knockout background without monoclonal selection, facilitating studies where population-level effects of target gene disruption are of interest.
The HAP1 host cell line is a near-haploid, adherent, fibroblast-like cell model originally derived from the KBM-7 chronic myeloid leukemia cell line from a male donor. Its near-haploid karyotype simplifies genetic analysis by reducing the complexity of diploid genomes, making it a powerful tool for genetic screens, functional genomics, and knockout validation. HAP1 cells maintain key signaling pathways relevant to cancer biology, including those involved in proliferation, apoptosis, and chromatin regulation, while offering ease of culture and genetic manipulation. The male origin of HAP1 cells is particularly advantageous for studying Y-linked genes such as KDM5D, as it avoids X-linked homolog compensation issues present in female cells.
At the molecular level, KDM5D encodes a histone lysine demethylase that specifically removes methyl groups from di- and tri-methylated lysine 4 on histone H3 (H3K4me2/3), a hallmark of active chromatin, thereby serving as a transcriptional repressor. KDM5D functions within the Sin3A/HDAC corepressor complex, directly interacting with HDAC1 and HDAC2, and associates with key transcriptional regulators such as the retinoblastoma protein (RB1) and androgen receptor (AR). Its activity is regulated upstream by androgen receptor signaling and testis-determining factor SRY, while downstream, KDM5D-mediated demethylation leads to suppression of target genes including KLF4, CDKN1A, HOX gene clusters, and AR-responsive genes. This positions KDM5D at the nexus of epigenetic regulation and hormonal signaling, linking histone modification dynamics to transcriptional programs in development and disease.
In the HAP1 model, knockout of KDM5D offers a precise platform to dissect its unique contributions to epigenetic control, particularly in the context of androgen-dependent and independent signaling. The male-derived near-haploid background minimizes genetic redundancy and simplifies characterization of chromatin modifications, gene expression changes, and protein interactions upon loss of KDM5D function. Given its role in spermatogenesis and its association with prostate cancer progression and male infertility, this model enables interrogation of Y chromosome-linked gene function and the impact on AR signaling and chromatin remodeling. Researchers can investigate how KDM5D ablation alters H3K4 methylation landscapes, disrupts Sin3A/HDAC complex activity, and influences cellular phenotypes such as proliferation and differentiation in a genetically tractable system.
Representative applications include epigenetic regulation studies employing ChIP-qPCR to profile H3K4me2/3 levels at promoters of target genes, Western blotting to assess KDM5D and downstream effectors, and RT-qPCR to quantify changes in gene expression of KLF4, CDKN1A, and AR targets. Transcriptome-wide analysis via RNA-seq can reveal global regulatory networks influenced by KDM5D. Cancer research applications involve prostate cancer and leukemia models, where cell proliferation assays, flow cytometric cell cycle analysis, and AR signaling reporter assays can delineate the gene??s role in oncogenic progression. Male infertility research can utilize the knockout cells to mimic disrupted spermatogenic gene programs. For further technical details or to discuss custom experimental strategies, please contact Ascent Research.
